Main Conference Day One

Monday, March 5, 2012

7:45 Networking Breakfast & Conference Registration

Networking Breakfast & Conference Registration

8:45 Chairperson’s Opening Remarks

Chairperson’s Opening Remarks

9:00 Panel: Creative Partnering – New Thinking, New Markets, New Deal Structures

Timothy J. Dolan, Corporate Business Development, Eli Lilly and Company
Gregory Miller, Head of Business and Corporate Development, Concert Pharmaceuticals Inc.
David Donabedian Ph.D., Vice President, Global New Deal Strategy and Development, GSK
D. Brian Kacedon, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Big Pharma is actively seeking global acquisitions, licensing and commercialization agreements as a means of filling revenue gaps. This session will discuss the questions: what are the recent situations where creative partnerships can be used to ink a deal? And what are the features of these deals that have generated successful licensing, acquisition and commercialization agreements?

Timothy J. Dolan

Corporate Business Development, Eli Lilly and Company

Gregory Miller

Head of Business and Corporate Development, Concert Pharmaceuticals Inc.

Greg currently leads business and corporate development at Concert Pharmaceuticals, a company that applies precision deuterium chemistry to create differentiated New Chemical Entities (NCEs). This platform has yielded several candidates currently in clinical stage development, and a robust library of earlier stage compounds. Through early partnering, alternative funding, and other collaborative ap [read more]

David Donabedian Ph.D.

Vice President, Global New Deal Strategy and Development, GSK

Dr. Donabedian is Vice President, Global New Deal Strategy and Development and is a member of the ceedd leadership team. In this role, he is accountable for setting the ceedd new deal portfolio strategy and composition and working closely with GSK worldwide business development to establish new alliances. Prior to this position, Dr. Donabedian was the Vice President of Strategic Alliances in GSK's [read more]

D. Brian Kacedon

Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP

D. Brian Kacedon is a partner at Finnegan, Henderson, Farabow, Garrett & Dunner LLP. His practice focuses on patent licensing and patent litigation work. Mr. Kacedon’s role in these matters has included assisting clients in conducting market assessments for their patents, conducting licensing negotiations, drafting licensing and settlement agreements, and participating in related l [read more]

10:00 Refreshment Break & Networking Opportunity

Refreshment Break & Networking Opportunity

10:30 Panel: New Strategies In Academic/Industry Collaborations

Zafrira Avnur, Ph.D., Head, Global Academic Innovation Partnering, Roche Partnering
Steven Hutchins, SVP Strategic Business Development, Evotec
Marc Malandro, Ph.D., CLP, RTTP, Associate Vice Chancellor For Technology Management And Commercialization, University of Pittsburgh
Neena Kadaba Ph.D., Director Of Industry Alliances, QB3

Collaborating with academia is one of the various strategies pharmaceutical companies are using to bring innovation to the industry and build up their early stage development pipelines. This discussion will cover recent examples of academic/industry collaborations including the variations in size and scope, the unique challenges they face in balancing different cultures and an assessment of how well this partnering model is working.

Zafrira Avnur, Ph.D.

Head, Global Academic Innovation Partnering, Roche Partnering

Zafrira Avnur, Ph.D., is Global Academic Innovation Partnering Head at Roche Partnering. She holds a post doctorate (Cancer Biology) from Stanford University, and a Ph.D. from Weizmann Institute (cell Biology). She was based in Palo Alto, California, USA, from 1987 until 2006, in various positions in the Research and Development area at Roche. Amongst the positions she held are Distinguished Scie [read more]

Steven Hutchins

SVP Strategic Business Development, Evotec

Mr. Hutchins has over twenty years experience in the pharmaceutical and CRO industries as both a buyer and seller of pharmaceutical research and development services. He spent over sixteen years at Merck in progressively responsible positions, twelve of which managing outsourcing in support of basic research and pre-clinical development. Then several years at BioDuro and WuXi AppTec in senior mana [read more]

Marc Malandro, Ph.D., CLP, RTTP

Associate Vice Chancellor For Technology Management And Commercialization, University of Pittsburgh

Marc Malandro serves as the Associate Vice Chancellor for Technology Management and Commercialization and oversees the technology commercialization and licensing activities of both the Office of Technology Management and the Office of Enterprise Development, Health Sciences at the University of Pittsburgh. He is also an Adjunct Professor in the Departments of Medicin [read more]

Neena Kadaba Ph.D.

Director Of Industry Alliances, QB3

Neena S. Kadaba, Ph.D. is the Director of Industry Alliances at QB3 (the California Institute for Quantitative Biosciences), a state institute that accelerates the commercialization of innovations from UCSF, UC Berkeley and UC Santa Cruz. Neena works to initiate collaborations between industry and faculty from these three campuses, to expand QB3’s pre-commercial funding programs and to support ear [read more]

11:30 Case Study: Daiichi Sankyo, Inc./Plexxikon - Part 1 Business Development

This case study will analyze the Daiichi Sankyo, Inc./Plexxikon deal in two parts. Part 1 of our 2 part series will delve into the motivations and rationale behind the strategic choice for Daiichi Sankyo, Inc. to acquire Plexxikon Inc. In order to fully cover the acquisition, Part 2 of our case study will take place at BioNetwork West 2012 where the case study will focus on the integration and operations of these two organizations

12:00 Networking Lunch

Networking Lunch

1:30 BioNetwork Round Tables

Delegates looking to learn best practices, practical solutions, and innovative business development strategies will find the BioNetwork Round Tables a most valuable experience. Here is your chance to sit down with your peers and engage in candid, interactive discussions with business development experts. Each topic is led by a table moderator - a subject matter expert - who will facilitate the idea exchange among participants. You do not need to choose a topic, instead, the moderator will move from one table to the next to ensure that you have the opportunity to discuss each topic area. Moderators will rotate every 30 minutes.Potential Topics Could Include:

Product Development In A New Era Of Healthcare And Reimbursement
Challenges For Out-licensing Multiple/Dual Implications
What Terms Are Outside The Standard Deal Model?
Benefits To Working With Companies That Offer Both Branded And Generics
Negotiating With VC and CVC
Understanding The Pieces Of The Puzzle In Roles VC, Banker
Developing Relationships With Investors
Criteria Used By VC And CVC When Evaluating A Pitch

If you are interested in moderating a round table, please contact Rachel.Tosi@wbresearch.com or 1.646.200.7524

3:00 Refreshment Break & Networking Opportunity

Refreshment Break & Networking Opportunity

3:30 Panel: Tailoring A Strategy To Capitalize On Opportunities In Emerging Markets

Carlos Garrido, Director, Business Development Latin America, AstraZeneca
James Hattersley, VP, Corp. Business Development, Sun Pharmaceutical Industries Inc.

When assessing global opportunities Big Pharma and Biotechs alike must tailor their approaches to the specific dynamics and challenges of each market. This session will assess the strengths and weaknesses and competitive landscape of the top tier emerging markets and then panelists will draw upon professional experiences to make recommendations for customizing a winning strategy for successful global partnering.

Carlos Garrido

Director, Business Development Latin America, AstraZeneca

10386.006_bioNetworkWest_2011_james_hattersley_sun

James Hattersley

VP, Corp. Business Development, Sun Pharmaceutical Industries Inc.

James Hattersley has over 24 years of successful leadership experience in biotechnology & pharmaceutical life sciences. From 1986 to 1995 Jim was responsible for drug delivery and NCE research at Alza Corporation and Abbott Laboratories. Since 1995 Jim has led strategic business growth including execution of several transactions of significant value at Eurand, Antares, and Sun Phar [read more]

4:30 Case Study: Sanofi’s Exploration Of Academic Collaborations For External Innovation

Shiv Krishnan, Ph.D, Senior Director, Scouting & Partnering (R&D), Sanofi

Although Sanofi’s acquisition of Genzyme received its fair share of attention, it’s only a part of Sanofi’s overall plans to further expand its partnerships and acquisitions. In this session Sanofi’s Shiv Krishnan, Senior Director Scouting & Partnering in Sanofi R&D will provide insight into Sanofi’s plans to further explore academic partnerships, including with Harvard and MIT.

Shiv Krishnan, Ph.D

Senior Director, Scouting & Partnering (R&D), Sanofi

Shiv Krishnan is currently Senior Director, Scouting & Partnering in Sanofi R&D based in Bridgewater, New Jersey. In this role he works closely with innovators in academia and biotech companies to identify exciting breakthroughs at all levels of the pharma value chain for sanofi-aventis’ priority areas. He works closely with 2 other peer groups (based in San Diego a [read more]

5:00 Networking Cocktail Reception sponsored by AriVan Research LLC

Networking Cocktail Reception sponsored by AriVan Research LLC






	Interested In Sponsoring?
	Send me email updates






	Interested In Sponsoring?
	Send me email updates

Main Conference Day One

Monday, March 5, 2012

Timothy J. Dolan Corporate Business Development, Eli Lilly and Company

Gregory Miller Head of Business and Corporate Development, Concert Pharmaceuticals Inc.

David Donabedian Ph.D. Vice President, Global New Deal Strategy and Development, GSK

D. Brian Kacedon Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Zafrira Avnur, Ph.D. Head, Global Academic Innovation Partnering, Roche Partnering

Steven Hutchins SVP Strategic Business Development, Evotec

Marc Malandro, Ph.D., CLP, RTTP Associate Vice Chancellor For Technology Management And Commercialization, University of Pittsburgh

Neena Kadaba Ph.D. Director Of Industry Alliances, QB3

Carlos Garrido Director, Business Development Latin America, AstraZeneca

James Hattersley VP, Corp. Business Development, Sun Pharmaceutical Industries Inc.

Shiv Krishnan, Ph.D Senior Director, Scouting & Partnering (R&D), Sanofi